Natural killer (NK) cells are critical immune effector cells in the fight against cancer. As NK cells in cancer patients are highly dysfunctional and reduced in number, adoptive transfer of large numbers of cytolytic NK cells and their potential to induce relevant anti-tumor responses are widely explored in cancer immunotherapy. Early studies from autologous NK cells have failed to demonstrate significant clinical benefit. In this review, the clinical benefits of adoptively transferred allogeneic NK cells in a transplant and non-transplant setting are compared and discussed in the context of relevant NK cell platforms that are being developed and optimized by various biotech industries with a special focus on augmenting NK cell functions.
Natural Killer (NK) cells are innate immune cells with the unique ability to recognize and kill virus-infected and cancer cells without prior immune sensitization. Due to their expression of the Fc receptor CD16, effector NK cells can kill tumor cells through antibody-dependent cytotoxicity, making them relevant players in antibody-based cancer therapies. The role of NK cells in other approved and experimental anti-cancer therapies is more elusive. Here, we review the possible role of NK cells in the efficacy of various anti-tumor therapies, including radiotherapy, chemotherapy, and immunotherapy, as well as the impact of these therapies on NK cell function.
Adoptive cell therapy (ACT) represents a promising alternative approach for patients with treatment-resistant metastatic melanoma. Lately, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor (CAR)-T cell therapy have shown improved clinical outcome, compared to conventional chemotherapy or immunotherapy. Nevertheless, they are limited by immune escape of the tumor, cytokine release syndrome, and manufacturing challenges of autologous therapies. Conversely, the clinical use of Natural Killer (NK) cells has demonstrated a favorable clinical safety profile with minimal toxicities, providing an encouraging treatment alternative. Unlike T cells, NK cells are activated, amongst other mechanisms, by the downregulation of HLA class I molecules, thereby overcoming the hurdle of tumor immune escape. However, impairment of NK cell function has been observed in melanoma patients, resulting in deteriorated natural defense. To overcome this limitation, “activated” autologous or allogeneic NK cells have been infused into melanoma patients in early clinical trials, showing encouraging clinical benefit. Furthermore, as several NK cell-based therapeutics are being developed for different cancers, an emerging variety of approaches to increase migration and infiltration of adoptively transferred NK cells towards solid tumors is under preclinical investigation. These developments point to adoptive NK cell therapy as a highly promising treatment for metastatic melanoma in the future.
The ability to kill tumor cells while maintaining an acceptable safety profile makes Natural Killer (NK) cells promising assets for cancer therapy. Strategies to enhance the preferential accumulation and activation of NK cells in the tumor microenvironment can be expected to increase the efficacy of NK cell-based therapies. In this study, we show binding of a novel bispecific single domain antibody (VHH) to both CD16 (FcRγIII) on NK cells and the epidermal growth factor receptor (EGFR) on tumor cells of epithelial origin. The bispecific VHH triggered CD16- and EGFR-dependent activation of NK cells and subsequent lysis of tumor cells, regardless of the KRAS mutational status of the tumor. Enhancement of NK cell activation by the bispecific VHH was also observed when NK cells of colorectal cancer (CRC) patients were co-cultured with EGFR expressing tumor cells. Finally, higher levels of cytotoxicity were found against patient-derived metastatic CRC cells in the presence of the bispecific VHH and autologous peripheral blood mononuclear cells or allogeneic CD16 expressing NK cells. The anticancer activity of CD16-EGFR bispecific VHHs reported here merits further exploration to assess its potential therapeutic activity either alone or in combination with adoptive NK cell-based therapeutic approaches.
E14525 Background: Resistance to epidermal growth factor receptor (EGFR) targeting therapy is a major limitation in metastatic colorectal cancer (mCRC). Moreover, NK cells in solid tumor patients are often dysfunctional and low in number. Adoptive NK cell therapy could overcome those limitations and toxicities related to anti-EGFR therapies. In this study, cytotoxicity of allogeneic NK cell products like activated peripheral blood NK cells (PBNK) and oNKord, an alternate source of umbilical cord blood stem cell derived NK cells, has been investigated against colon cancer cells. Methods: Flow cytometry based NK cell cytotoxicity assays were performed, PBNK were co-cultured with various colon cancer cell lines coated or non-coated with cetuximab and their cytotoxicity was compared with oNKord. Results: Cetuximab as monotherapy was ineffective in killing EGFR+ RASmut, EGFR+ BRAFmut and EGFR- RASwt cells, whereas activated PBNK were able to initiate lysis of colon cancer cells. Cytotoxicity was further potentiated significantly (p < 0.01) upon coating colon cancer cells with cetuximab, including EGFR+ primary colon tumors (n = 5; 3 RASwt, 2 RASmut) with a cytotoxicity of 36 ± 5%, p < 0.05. More importantly, a significant (p < 0.01) higher cytotoxicity was induced by oNKord in EGFR+ RASmut (38 ± 4% vs 61 ± 5%), EGFR+ BRAFmut (36 ± 4% vs 59 ± 3% ) and EGFR- RASwt (42 ± 8% vs 67 ± 7% ) colon cancer cells compared to PBNK + cetuximab conditions. Conclusions: Activated NK cells are able to eliminate colon cancer cell lines and primary colon tumor cells.oNKord showed enhanced anti-tumor cytotoxicity against colon cancer independent of EGFR, RAS and BRAF status. As oNKord has proven safety in a phase I clinical trial in acute myeloid leukemia (AML), a fast translation towards clinical proof of concept in mCRC is feasible. A clinical study to further develop oNKord immunotherapy in mCRC patients has been planned to start this year.
E14526 Background: Cetuximab monotherapy is not effective in epidermal growth factor receptor (EGFR) positive cervical cancer patients. NK cells synergize with cetuximab through antibody dependent cellular cytotoxicity (ADCC) to lyse cervical cancer cells. As NK cells of cancer patients are dysfunctional and low in number, adoptive NK cell infusion could overcome those limitations. Allogeneic NK cell products, like cord blood derived NK cells (oNKord), have shown safety in clinical trials serving as promising treatment option.Methods: Activated peripheral blood NK cells (PBNK) were cultured with ten various cervical cancer cell lines, coated or non-coated with cetuximab. Their cytotoxic effect was compared with oNKord cells using flow cytometry based NK cell cytotoxicity assays. Results: While cetuximab monotherapy was ineffective, activated PBNK were capable of lysing cervical cancer cells, in vitro (p < 0.05), and this cytotoxic effect was further increased (p < 0.01) on cetuximab coated tumor targets (n = 5). PBNK and oNKord cytotoxicity was positively regulated by NK activating receptors NKG2D and DNAM-1 (p < 0.05), as supported by blocking experiments. Significantly (p < 0.01) higher cytotoxicity was induced by oNKord compared to activated PBNK (7/10). Moreover, oNKord cytotoxicity was higher compared to PBNK + cetuximab in CSCC7 (23 ± 2% vs 36 ± 5%), CC8 (36 ± 8% vs 51 ± 9%), HeLa (19 ± 5% vs 30 ± 4%) and equal to the cytotoxic efficacy of PBNK + cetuximab in other cell lines. Importantly, correlation analysis of PBNK and oNKord cytotoxicity showed independency related to HLA-E and G levels. PBNK showed a strong inhibition of cytolytic activity (p = 0.05) with increasing HLA-ABC expression levels, whereas oNKord cytotoxicity was entirely independent (p = 0.72) of HLA-ABC expression.Conclusions: Superior anti-tumor effects and the ability to overcome target cell resistance, makes adoptive transfer of oNKord an effective and novel immunotherapeutic strategy for cervical cancer. A first in human proof of concept trial to treat cervical cancer patients with oNKord is planned to start end 2016.